Source comparison
CJC-1295 no DAC & Ipamorelin Side Effects: Research vs Anecdotal Comparison
Understanding the difference between documented research findings and commonly reported anecdotal experiences clarifies which side effects are physiologically expected and which likely reflect protocol errors or product quality issues. Injection Site Reactions
This comparison does not assign a generated winner or score.
- Understanding the difference between documented research findings and commonly reported anecdotal experiences clarifies which side effects are physiologically expected and which likely reflect protocol errors or product quality issues.
- Injection Site Reactions
- 22–28% incidence in controlled trials; erythema and mild pain resolving within 48–72 hours
- Frequently reported; some cases describe persistent nodules or severe inflammation
- Persistent reactions suggest reconstitution contamination or injection technique errors. Not inherent peptide properties
- Water Retention
- 12–18% in clinical studies; dose-dependent, peaks at days 3–5, resolves by week 3
- Widely reported; often cited as reason for discontinuation
- True GH-mediated effect; can be mitigated with sodium restriction and dose adjustment
- Headaches
- 8–15% during initial 10–14 days; correlates with rapid IGF-1 increases
- Common in first 2 weeks; rarely persists beyond that window
- Expected adaptation response; severe or persistent cases warrant dose reduction
- Joint Discomfort
- Rare in standard-dose protocols (<5%); increases with doses >300mcg combined
- Frequently reported, especially in older users or those with pre-existing joint conditions
- Likely reflects supraphysiological GH levels or underlying conditions unmasked by increased GH activity
- Cortisol Elevation
- Minimal with Ipamorelin; CJC-1295 no DAC shows negligible impact on ACTH/cortisol axis
- Anxiety and sleep disruption sometimes attributed to cortisol
- More likely reflects dosing too close to bedtime or confusion with earlier-generation GHRPs
- Hypoglycemia
- Not documented in healthy subjects; glucose increases more common
- Occasionally reported, particularly post-administration
- May reflect dietary timing or concurrent insulin-sensitizing medication interactions